There may be a new scientific breakthrough that could revolutionize how the body absorbs cannabidiol (CBD). This can result in safer, more effective, and less expensive treatments.

CBD is famously known to assist with pain, inflammation, and brain protection. It has been used to assist in treating conditions such as epilepsy, multiple sclerosis, and chronic pain. Yet, one of the greatest issues that keep CBD from being effective is that it is poorly absorbed.

CBD is not soluble in water, meaning that the body can't digest it when consumed orally. What that implies is that a significant amount of the CBD individuals consume doesn't find its way into the bloodstream in significant quantities.

Finally, researchers at the University of South Australia (UniSA) have solved this issue by significantly enhancing the bioavailability of CBD absorption using a phospholipid complex.

The new system employs a fat-based molecule that contains phosphorus to form minute particles known as a CBD-PLC (CBD-phospholipid complex). It facilitates the ease with which CBD dissolves within the body and enhances the amount that is absorbed and delivered where it is required.

The study found that these advanced particles helped CBD to dissolve from 0% to a whopping 67.1% in just three hours.

This is a significant breakthrough for CBD-based therapies," said Thabata Muta, lead author and UniSA PhD student. "Improved CBD absorption allows patients to achieve improved outcomes at lower doses, minimizing side effects and cost of treatment.".

The researchers also reported that there was an increase in permeability by 32.7% in tests on cells. This would allow more of the CBD to pass through the intestinal lining and into the bloodstream.

Another advantage is that the formulation is stable for a longer duration. Unlike traditional CBD products that can degrade upon exposure to heat, light, or oxygen, the new phospholipid complex was stable even after 12 months of storage.

This improvement benefits CBD users and could also provide a lead to better utilization of other insoluble medication.

The global CBD market is expected to grow from $7.59 billion in 2023 to over $200 billion by 2032. This discovery comes at the ideal time.

Pharmaceutical firms have attempted to make CBD absorption easy with man-made equivalents, emulsions, or gel capsules — but they have side effects or act erratically. The UniSA researchers' approach does not involve artificial additives and uses materials that are naturally compatible with the body membranes, and is therefore more comfortable and a safer option.

The scientists are preparing for clinical trials and searching for means of marketing this breakthrough. If it succeeds, this may lead to more effective and consistent CBD medications — particularly for individuals with epilepsy, multiple sclerosis, anxiety, and pain.

In short, this new way of CBD absorption can now enable us to utilize all the medicinal value of cannabidiol to the fullest. It can provide patients with more consistent, safer, and less expensive treatments for most serious diseases.